With Tania de Jong AM
Date: Mon 13 September 2021 @ 7:00pm
Location: Online
Mind Medicine Australia is pleased to invite you to participate in an important educational webinar for ANZCCP members.
Webinar: Psychedelic-assisted therapies for mental illness: why innovation in treatment is needed now more than ever.
Date: Monday 13 September 2021
Time: 7:00 – 8:00 pm (AEST)
Pre-Covid 1 in 5 people in Australia were suffering from a mental illness. At least 1 in 8 adults, 1 in 4 older adults in 1 in 30 children are on anti-depressant medications currently, and often without disclosure of potential side effects. There has been no innovation in existing treatments for 5 decades. The lack of effective treatments has most certainly contributed to Australia’s devastating mental health statistics, which position Australia as second worst amongst all OECD nations, only ahead of Iceland. As a result of the Covid-19 pandemic many more Australians are experiencing anxiety, trauma, addiction, depression, loneliness and social isolation, and suicide rates could significantly increase in the absence of innovation in treatments.
In the quest for new treatment options for mental illness and psychiatric disorders, attention is being paid to the potential role of psychedelic medicines as adjuncts to psychotherapy for a wide array of conditions, including depression, anxiety, post-traumatic stress disorder and some addictions. Trials are also underway for dementia, Parkinson’s, strokes, cluster headaches, OCD and eating disorders. A proactive approach to broadening the treatment options available for people who have a mental illness is desperately needed.
This keynote and Q & A Session is presented by Mind Medicine Australia. The session will provide an engaging and educational update incorporating new learnings, science and data about innovative, safe and effective treatments being used in a practical clinical setting. It will also provide information on how to access the TGA’s SAS-B pathway for psilocybin and MDMA assisted therapies for treatment-resistant patients on a case-by-case basis.
Learning objectives:
More About Medicinal MDMA:
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
Results from Phase 2 clinical trials over the past decade have been so compelling that the Food and Drug Administration (FDA) in the United States recently designated MDMA-assisted psychotherapy as a ‘Breakthrough Therapy’. This designation highlights the FDA’s anticipation that these therapies may offer substantial advantage over current treatments. If forthcoming Phase 3 results confirm these treatments are effective, MDMA-assisted treatment of PTSD may become a prescription medicine as early as 2021 in some jurisdictions.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
LL.B (Hons), GradDipMus
Tania de Jong AM is the co-Founder and Executive Director of Mind Medicine Australia. She regularly presents on psychedelic-assisted therapies, mental health and wellbeing at major conferences and events around the world and to Governments, regulators, clinicians, philanthropists and the general public.
Tania is one of Australia’s most successful female entrepreneurs and innovators developing 6 businesses and 4 charities including Creative Universe, Creativity Australia and With One Voice, Umbrella Foundation, Creative Innovation Global, Pot-Pourri and The Song Room.
Tania was named in the 100 Women of Influence, the 100 Australian Most Influential Entrepreneurs and named as one of the 100 most influential people in psychedelics globally in 2021. Tania’s TED Talk has sparked international interest. Tania has garnered an international reputation as a performer, speaker, entrepreneur and a passionate leader for social change. Her mission is to change the world, one voice at a time!
Disclaimer: Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example Facebook, Instagram or Zoom private and public chat forms during a webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.
